Janus Henderson Group PLC Takes Position in Qiagen N.V. $QGEN

Janus Henderson Group PLC acquired a new position in shares of Qiagen N.V. (NYSE:QGEN) in the first quarter, Holdings Channel.com reports. The fund acquired 366,661 shares of the company’s stock, valued at approximately $14,647,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Amundi increased its stake in Qiagen by 12.4% in the first quarter. Amundi now owns 4,757,681 shares of the company’s stock valued at $190,498,000 after acquiring an additional 524,959 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Qiagen by 46.8% during the first quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company’s stock worth $110,000 after purchasing an additional 876 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Qiagen by 23.2% in the 1st quarter. Royal Bank of Canada now owns 27,957 shares of the company’s stock worth $1,118,000 after purchasing an additional 5,271 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of Qiagen in the 1st quarter worth about $2,518,000. Finally, Sona Asset Management US LLC bought a new position in shares of Qiagen during the 1st quarter valued at about $8,891,000. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on QGEN. Weiss Ratings cut Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 29th. Berenberg Bank set a $45.50 price target on shares of Qiagen and gave the company a “hold” rating in a research report on Tuesday, July 14th. Barclays set a $38.00 price target on shares of Qiagen and gave the stock an “equal weight” rating in a research note on Wednesday, April 29th. Kepler Capital Markets set a $38.60 price objective on shares of Qiagen and gave the stock a “hold” rating in a report on Thursday, June 25th. Finally, Zacks Research raised shares of Qiagen from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $43.34.

Qiagen Stock Performance

Shares of QGEN stock opened at $42.34 on Wednesday. The stock has a fifty day moving average of $39.10 and a 200 day moving average of $41.77. Qiagen N.V. has a 52 week low of $32.53 and a 52 week high of $57.81. The firm has a market capitalization of $8.73 billion, a price-to-earnings ratio of 22.11, a PEG ratio of 4.22 and a beta of 0.63. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.54 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.54. The business had revenue of $492.32 million for the quarter, compared to the consensus estimate of $496.15 million. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. During the same period in the previous year, the firm earned $0.56 EPS. As a group, research analysts expect that Qiagen N.V. will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The business also recently announced an annual dividend, which was paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th were given a $0.35 dividend. The ex-dividend date of this dividend was Tuesday, July 7th. This represents a dividend yield of 90.0%. This is a positive change from Qiagen’s previous annual dividend of $0.26. Qiagen’s dividend payout ratio is 18.32%.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.